| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-03-07 | Oxford BioMedica (UK) Immune Design Corp (USA) | lentiviral vector-based products | cancer, chronic diseases | services contract |
Cancer - Oncology | Services contract |
| 2016-03-07 | Abbvie (USA - IL) Boehringer Ingelheim (Germany) | BI 655066, BI 655064 | asthma, Crohn's disease, psoriasis, psoriatic arthritis | development commercialisation |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Respiratory diseases | Development agreement |
| 2016-03-07 | Myokardia (USA - CA) | nomination |
Cardiovascular diseases | Nomination | ||
| 2016-03-07 | Avexis (USA - IL) | nomination |
Rare diseases - Genetic diseases - Neurological diseases | Nomination | ||
| 2016-03-07 | Avacta (UK) | nomination |
Diagnostic | Nomination | ||
| 2016-03-07 | Ferring Pharmaceuticals (Switzerland) | Asia Pacific headquarters in Singapore | opening of new premises |
Gastrointestinal diseases - Digestive diseases - Women health - Fertility - Endocrinological diseases - Hormonal diseases | Opening of new premises | |
| 2016-03-04 | Amarantus BioScience (USA – CA) | nomination |
Rare diseases - Regenerative medicine | Nomination | ||
| 2016-03-03 | Chugai Pharmaceutical (Japan) Biomarin Pharmaceutical (USA - CA) | C-type natriuretic peptide (CNP) | achondroplasia | licensing |
Rare diseases - Genetic diseases | Licensing agreement |
| 2016-03-03 | Merck KGaA (Germany) the European Molecular Biology Laboratory (EMBL) (Germany) | R&D collaboration |
Cancer - Oncology | R&D agreement | ||
| 2016-03-03 | Merck KGaA (Germany) Pfizer (USA - NY) Verastem (USA - CA) | avelumab (MSB0010718C) and VS-6063 (defactinib - N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride) | advanced ovarian cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-03-03 | Grünenthal (Germany) Axxam (Italy) | small molecule lead structures | pain, inflammatory diseases | development collaboration |
CNS diseases - Neurological diseases - Inflammatory diseases | Development agreement |
| 2016-03-03 | Medivir (Sweden) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2016-03-03 | Osiris Therapeutics (USA - MD) | nomination |
Regenerative Medicine | Nomination | ||
| 2016-03-03 | Autolus (UK) | chief executive officer | nomination | Cancer - Oncology | Nomination | |
| 2016-03-02 | Sanofi (France) Institut Gustave Roussy - IGR (France) | various candidates from Sanofi oncology pipeline - MOSCATO study | various cancers | R&D |
Cancer - Oncology | Clinical research agreement |
| 2016-03-02 | Arsanis (USA - MA) | nomination |
Infectious diseases | Nomination | ||
| 2016-03-02 | Horizon Discovery (UK) Centauri Therapeutics (UK) Avvinity Therapeutics (UK) | joint venture | Cancer - Oncology | Joint-venture agreement | ||
| 2016-03-01 | Eurofins Scientific (France) | manufacturing and services facility in Louisville | opening of new premises |
Technology - Services | Opening of new premises | |
| 2016-03-01 | JHL Biotech (Taiwan) Affinita Biotech (USA - CA) | oncology monoclonal antibodies | production manufacturing |
Technology - Services | Production agreement | |
| 2016-03-01 | AstraZeneca (UK) Prostrakan, a subsidiary of Kyowa Hakko Kirin (Japan) | Moventig® (naloxegol) | opioid-induced constipation in adult patients who have had an inadequate response to laxative(s) | licensing - commercialisation | Gastrointestinal diseases - Digestive diseases | Product acquisition |
